Citigroup’s Abeona Therapeutics ABEO Stock Holding History

Citigroup’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-70,000	Closed	-$297K	–	5661
2024 Q2	$297K	Buy	+70,000	New	+$357K	﹤0.01%	3687
2020 Q1	–	Sell	-192	Closed	-$16K	–	7574
2019 Q4	$16K	Sell	192 -212	-52%	-$15K	﹤0.01%	7013
2019 Q3	$23K	Buy	404 +24	+6%	+$1.8K	﹤0.01%	6640
2019 Q2	$45K	Sell	380 -128	-25%	-$21.5K	﹤0.01%	6566
2019 Q1	$93K	Buy	508 +104	+26%	+$18.6K	﹤0.01%	5809
2018 Q4	$72K	Sell	404 -112	-22%	-$24.4K	﹤0.01%	5926
2018 Q3	$165K	Sell	516 -4	-0.8%	-$1.42K	﹤0.01%	5437
2018 Q2	$208K	Buy	520 +312	+150%	+$136K	﹤0.01%	5025
2018 Q1	$75K	Buy	+208	New	+$77.3K	﹤0.01%	5851

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OIA

OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup's ABEO Position: Q2 2026 in Review

Citigroup increased its Abeona Therapeutics (ABEO) stake by 4.9% in Q2 2026, buying an estimated $142K and bringing the position to 548,300 shares worth $3.39M. The position accounts for ﹤0.01% of the portfolio, ranked #2487.

Citigroup first reported a position in ABEO in Q2 2015 and has held it in 37 quarters since. The position peaked at $3.9M in Q3 2024. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

Citigroup held 548,300 shares of Abeona Therapeutics worth $3.39M as of Q2 2026.
Citigroup bought 25,855 Abeona Therapeutics shares in Q2 2026, an estimated $142K.
Abeona Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2487 holding.
Citigroup first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 37 quarters since.
Citigroup's Abeona Therapeutics position peaked at $3.9M in Q3 2024.
126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.